AER-271 (C007B-326362)

AER-271, a phosphonate proagent derivative of AER-270, is an aquaporin-4 ( AQP4 ) inhibitor for the research of acute ischemic strokeIn VivoAER-271 is converted in vivo to AER-270 by endogenous phosphatases. AER-271 blocks acute cerebral edema and improves early outcome in a pediatric model of asphyxial cardiac arrest . AER-271 reduces cerebral edema and improves neurological outcomes in rodent ischemic stroke models. Mice treated with AER-271 (5 mg/kg; i.p. injection) show improved outcomes and reduced cerebral edema in a model of ischemic stroke. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male mice (C57BL/6J, 8-12 week-old, 25-30 g)Dosage: 5 mg/kg Administration: Treated by i.p. injection Result: Had better outcomes with an average neurological score of 0.89±0.31 compared with control mice receiving vehicle had an average neurological score of 2.50±0.62.IC50& Target:Aquaporin-4 (AQP4).

Specifications and Purity: 10mM in DMSO

Molecular Formula: C15H9ClF6NO5P

Molecular Weight: 463.65